European neonatal specialists have published the first ESPR recommendation, a structured Vascular Access Management Plan ...
Experts point to a possible IV failure in Pike's botched execution as questions surround Tennessee's secretive process for obtaining lethal drugs.
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the ...
A prospective, multicenter real-world study, dubbed ADHERE REAL (NCT07264426), will evaluate the effectiveness of ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, will present new data from across its portfolio and pipeline at the 2026 American Association ...
As an Amazon Associate, Yuta earns from qualifying purchases.Hello, this is Yuta.Is one spare battery for the α7 IV enough?
9dOpinion
Leg pain can warn of a serious condition: Why peripheral artery disease (PAD) needs more attention
Pain in your legs when you walk may seem like a normal part of getting older. But it can be a warning sign that the arteries ...
Five-year overall survival rate was reported at 69.2%, indicating strong long-term efficacy of CARVYKTI in treating ...
About CARVYKTI® CARVYKTI ® (cilta-cel) received U.S. Food and Drug Administration approval in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after four or more ...
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line ...
You are establishing an IV line for a conscious pregnant patient. You choose a thinner 20G needle because you think it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results